Enliven Therapeutics, Inc. announced updated positive Phase 1 ENABLE clinical trial data for ELVN-001 in patients with chronic myeloid leukemia, showing a 54% major molecular response rate in the overall Phase 1b cohort and 61% in the 80 mg QD cohort. The FDA selected 80 mg QD as the recommended dose for the upcoming Phase 3 ENABLE-2 trial. Enliven Therapeutics, Inc. is a biotechnology company focused on developing therapeutic candidates for cancer patients.
